The Secretory of the Department of Health and Human Services has declared a public health emergency that justifies the emergency use of bamlanivimab to treat coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection. In response, the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the unapproved product, bamlanivimab, for the treatment of COVID-19.

- Bamlanivimab has not been approved, but has been authorized for emergency use by FDA, to treat mild to moderate COVID-19 in adults, and also pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.

- Bamlanivimab is authorized for the treatment of mild to moderate COVID-19 in adults, and also pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of bamlanivimab under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

The FDA issued this EUA, requested by Eli Lilly and Company and based on their submitted data. Find more information in the FDA Letter of Authorization. Healthcare providers should review the Fact Sheet for Healthcare Providers for important information on the authorized use of bamlanivimab and mandatory requirements of the EUA.

This document was developed by Eli Lilly and Company as a resource for health programs to respond to the COVID-19 pandemic using bamlanivimab antibody treatment. The recommendations in this document apply only to bamlanivimab when administered alone.
# Table of Contents

Executive Summary ......................................................................................................................... 3

Section 1: Population for Antibody Treatment and Regulatory Notices ........................................... 4

Mandatory Requirements for Bamlanivimab Administration Under Emergency Use Authorization .......... 8

Important Safety Information ............................................................................................................. 11

Section 2: Scaling Operations ......................................................................................................... 13

Section 3: Infusion Site of Care Recommendations ......................................................................... 15

Preparation, Storage and Handling .................................................................................................. 16

Compatible Materials ...................................................................................................................... 17

Preparation and Administration ....................................................................................................... 17

Section 4: Recommended Infusion Site of Care Resources and Equipment Considerations ............... 20

Staffing Recommendations .............................................................................................................. 21

Infusion Site of Care Materials ....................................................................................................... 22

Section 5: Considerations for Residents of Long Term Care Facilities ........................................... 23

Receiving Infusion Treatments .......................................................................................................... 24

Long Term Care Recommended Resources and Equipment Considerations ..................................... 24

Section 6: Education and Awareness .............................................................................................. 25

Appendix A: Lilly Monoclonal Antibody Clinical Trial Modeling Information ................................. 29

Appendix B: Basic Equipment Recommendations ............................................................................. 31
EXECUTIVE SUMMARY

The world is currently in the midst of a global pandemic. As a global pharmaceutical company, we feel a responsibility to do our part to relieve the burden COVID-19 has placed on countries, communities and families around the world.

Clinical trials have shown that monoclonal antibodies may be effective in treating COVID-19. Lilly in partnership with AbCellera has developed a monoclonal antibody called bamlanivimab. Bamlanivimab is a recombinant neutralizing human IgG1 monoclonal antibody directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus.

This Playbook provides information for state, territorial and local public health programs to plan and operationalize a bamlanivimab antibody response to COVID-19. The sections of this document cover specific areas of COVID-19 antibody program planning and implementation, as well as links to resources to assist with those efforts. The sections described in this Playbook may also overlap with routine monoclonal antibody treatment and infusion program activities. This Playbook represents guidance based on Lilly’s Clinical Trial experience in monoclonal antibody treatments and should not supersede local recommendations for infusion sites of care. Please defer to local guidelines.

Healthcare providers should review the Fact Sheet for information on the authorized use of bamlanivimab and mandatory requirements of the EUA.

In addition, the Playbook includes information regarding planning and implementation based on varying infusion sites of care, such as:

- Existing hospital or community-based infusion sites of care
- Existing clinical space (e.g., primary care practices affiliated with hospital systems, urgent care locations, emergency departments, surgery centers, dialysis centers, plasma centers, respiratory clinics and other healthcare delivery entities approved to administer infusion therapies)
- Long term care facilities

We expect most infusion treatments will be administered in one of these aforementioned infusion sites of care, but other infusion sites of care may also be considered. This Playbook provides information that may or may not be applicable to certain spaces depending on existing capabilities.
Population for Antibody Treatment and Regulatory Notices
POPULATION FOR ANTIBODY TREATMENT

This EUA is for the use of the unapproved product bamlanivimab for the treatment of mild to moderate† COVID-19 in adults, and also pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.

Limitations of Authorized Use

Benefit of treatment with bamlanivimab has not been observed in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bamlanivimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation. Therefore, bamlanivimab is not authorized for use in patients:

• who are hospitalized due to COVID-19, OR
• who require oxygen therapy due to COVID-19, OR
• who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.

For more information, reference the Fact Sheet for Healthcare Providers.

Antiviral Resistance

Circulating SARS-CoV-2 viral variants may be associated with resistance to monoclonal antibodies. Healthcare providers should review the Antiviral Resistance information in Section 15 of the Fact Sheet for Healthcare Providers for details regarding specific variants and resistance, and refer to the CDC website as well as information from state and local health authorities regarding reports of viral variants of importance in their region to guide treatment decisions.

The use of alternative authorized monoclonal antibodies that are expected to retain activity against circulating viral variants may reduce the potential risk of treatment failure should a patient be infected with a SARS-CoV-2 viral variant that is resistant to bamlanivimab alone.

† Patients with mild COVID-19 illness may exhibit a variety of signs and symptoms (e.g., fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell). They do not have shortness of breath, dyspnea on exertion, or abnormal imaging.

Moderate COVID-19 illness is defined as evidence of lower respiratory disease during clinical assessment or imaging, with SpO₂ ≥94% on room air at sea level.

Source: National Institutes of Health
**Patient Selection**

High risk is defined as patients who meet at least one of the following criteria:

- Have a body mass index (BMI) \(\geq 35\)
- Have chronic kidney disease
- Have diabetes
- Have immunosuppressive disease
- Are currently receiving immunosuppressive treatment
- Are \(\geq 65\) years of age
- Are \(\geq 55\) years of age AND have
  - cardiovascular disease, OR
  - hypertension, OR
  - chronic obstructive pulmonary disease/other chronic respiratory disease.
- Are 12 - 17 years of age AND have
  - BMI \(\geq 85\)th percentile for their age and gender based on CDC growth charts, [https://www.cdc.gov/growthcharts/clinical_charts.htm](https://www.cdc.gov/growthcharts/clinical_charts.htm), OR
  - sickle cell disease, OR
  - congenital or acquired heart disease, OR
  - neurodevelopmental disorders, for example, cerebral palsy, OR
  - a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), OR
  - asthma, reactive airway or other chronic respiratory disease that requires daily medication for control.
**Bamlanivimab must be administered by intravenous (IV) infusion.**

Bamlanivimab may only be administered in settings in which healthcare providers have immediate access to medications to treat a severe infusion reaction, such as anaphylaxis, and the ability to activate the emergency medical system (EMS), as necessary.

Healthcare providers must submit a report on all medication errors and **ALL SERIOUS ADVERSE EVENTS** potentially related to bamlanivimab. See Sections 8 and 9 of the Fact Sheet for Healthcare Providers for reporting instructions below.

**Preparation and Administration**

- The authorized dosage for bamlanivimab is a single intravenous (IV) infusion of 700 mg administered as soon as possible after positive results of direct SARS-CoV-2 viral testing and within 10 days of symptom onset.
- Bamlanivimab is available as a solution and must be diluted prior to administration.
- Administer bamlanivimab 700 mg as a single IV infusion via pump or gravity (See Table 1).
- Clinically monitor patients during administration and observe patients for at least 1 hour after infusion is complete.
- Patients treated with bamlanivimab should continue to self-isolate and use infection control measures (e.g., wear mask, isolate, social distance, avoid sharing personal items, clean and disinfect “high touch” surfaces, and frequent handwashing) according to CDC guidelines.

For full Preparation and Administration information, please see Section 3: Infusion Site of Care Recommendations.

The authorized dosage may be updated as additional data from clinical trials becomes available.

For information on clinical trials that are testing the use of bamlanivimab in COVID-19, please see [www.clinicaltrials.gov](http://www.clinicaltrials.gov).
**Mandatory Requirements for Bamlanivimab Administration Under Emergency Use Authorization**

In order to mitigate the risks of using this unapproved product under the EUA and to optimize the potential benefit of bamlanivimab, the following items are required. Use of bamlanivimab under this EUA is limited to the following (all requirements **must** be met):

1. Treatment of mild to moderate COVID-19 in adults, and also pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization [see Limitations of Authorized Use].

2. As the healthcare provider, communicate to your patient or parent/caregiver, as age appropriate, information consistent with the [Fact Sheet for Patients, Parents and Caregivers](#) prior to the patient receiving bamlanivimab. Healthcare providers (to the extent practicable given the circumstances of the emergency) must document in the patient’s medical record that the patient/caregiver has been:
   a. Given the [Fact Sheet for Patients, Parents and Caregivers](#),
   b. Informed of alternatives to receiving authorized bamlanivimab, and
   c. Informed that bamlanivimab is an unapproved drug that is authorized for use under this Emergency Use Authorization.

3. Patients with known hypersensitivity to any ingredient of bamlanivimab must not receive bamlanivimab.

4. The prescribing healthcare provider and/or the provider’s designee are/is responsible for mandatory reporting of all medication errors and serious adverse events* potentially related to bamlanivimab treatment within 7 calendar days from the onset of the event. The reports should include unique identifiers and the words “Bamlanivimab treatment under Emergency Use Authorization (EUA)” in the description section of the report.

   • **Submit adverse event reports to FDA MedWatch using one of the following methods:**
     • Complete and submit the report online: [www.fda.gov/medwatch/report.htm](http://www.fda.gov/medwatch/report.htm), or
     • Use a postage-paid Form FDA 3500 (available at [http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM163919.pdf](http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM163919.pdf)) and return it by mail (MedWatch, 5600 Fishers Lane, Rockville, MD 20852-9787), or by fax (1-800-FDA-0178), or
     • Call 1-800-FDA-1088 to request a reporting form
     • Submitted reports should include in the field name, “Describe Event, Problem, or Product Use/Medication Error” the statement “Bamlanivimab treatment under Emergency Use Authorization (EUA)”
*Serious Adverse Events are defined as:

- death;
- a life-threatening adverse event;
- inpatient hospitalization or prolongation of existing hospitalization;
- a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions;
- a congenital anomaly/birth defect;
- a medical or surgical intervention to prevent death, a life-threatening event, hospitalization, disability or congenital anomaly.

5. The prescribing healthcare provider and/or the provider’s designee are/is to provide mandatory responses to requests from FDA for information about adverse events and medication errors following receipt of bamlanivimab.

6. Other Reporting Requirements

- Healthcare facilities and providers must report therapeutics information and utilization data through HHS Protect, Teletracking or National Healthcare Safety Network (NHSN) as directed by the U.S. Department of Health and Human Services.
- In addition, please provide a copy of all FDA MedWatch forms to:
  Eli Lilly and Company, Global Patient Safety
  Fax: 1-317-277-0853
  E-mail: mailindata_gsmtindy@lilly.com
  Or call Eli Lilly and Company at 1-855-LillyC19 (1-855-545-5921) to report adverse events.

Approved Available Alternatives

There is no adequate, approved and available alternative to bamlanivimab for patients who have mild to moderate COVID-19 who are at high risk for progressing to severe COVID-19 and/or hospitalization. Additional information on COVID-19 treatments can be found at https://www.cdc.gov/coronavirus/2019-ncov/index.html. The healthcare provider should visit https://clinicaltrials.gov/ to determine whether the patient may be eligible for enrollment in a clinical trial.
Authority for Issuance of the EUA

The Secretary of the Department of Health and Human Services (HHS) has declared a public health emergency that justifies the emergency use of drugs and biological products during the COVID-19 pandemic. FDA has issued this EUA, requested by Eli Lilly and Company for the unapproved product bamlanivimab for the treatment of mild to moderate COVID-19 in adults, and also pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization¹. As a healthcare provider, you must comply with the mandatory requirements of the EUA (see above).

Although limited scientific information is available, based on the totality of the scientific evidence available to date, it is reasonable to believe that bamlanivimab may be effective for the treatment of mild to moderate COVID-19 in certain high-risk patients as specified in this Fact Sheet. You may be contacted and asked to provide information to help with the assessment of the use of the product during this emergency.

This EUA for bamlanivimab will end when the Secretary determines that the circumstances justifying the EUA no longer exist or when there is a change in the approval status of the product such that an EUA is no longer needed.

Contact Information

For additional information visit www.bamlanivimab.com

If you have questions, please contact 1-855-LillyC19 (1-855-545-5921)

¹The health care provider should visit clinicaltrials.gov to determine whether there is an active clinical trial for the product in this disease/condition and whether enrollment of the patient(s) in a clinical trial is more appropriate than product use under this EUA.
IMPORTANT SAFETY INFORMATION

There are limited clinical data available for bamlanivimab. Serious and unexpected adverse events may occur that have not been previously reported with bamlanivimab use.

WARNINGS

Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions

Serious hypersensitivity reactions, including anaphylaxis, have been observed with administration of bamlanivimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.

Infusion-related reactions have been observed with administration of bamlanivimab. These reactions may be severe or life threatening.

Signs and symptoms of infusion-related reactions may include:

- fever, difficulty breathing, reduced oxygen saturation, chills, fatigue, arrhythmia (e.g. atrial fibrillation, sinus tachycardia, bradycardia), chest pain or discomfort, weakness, altered mental status, nausea, headache, bronchospasm, hypotension, hypertension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, dizziness, and diaphoresis.

If an infusion-related reaction occurs, consider slowing or stopping the infusion and administer appropriate medications and/or supportive care.

Clinical Worsening After Bamlanivimab Administration

Clinical worsening of COVID-19 after administration of bamlanivimab has been reported and may include signs or symptoms of fever, hypoxia or increased respiratory difficulty, arrhythmia (e.g., atrial fibrillation, sinus tachycardia, bradycardia), fatigue, and altered mental status. Some of these events required hospitalization. It is not known if these events were related to bamlanivimab use or were due to progression of COVID-19.
**Limitations of Benefit and Potential Risk in Patients with Severe COVID-19**

Benefit of treatment with bamlanivimab has not been observed in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bamlanivimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation. See Limitations of Authorized Use on page 5 of this Playbook.

**Adverse Events**

Adverse events reported in at least 1% of BLAZE-1 clinical trial participants on bamlanivimab 700 mg or placebo were nausea (3% vs 4%), diarrhea (1% vs 5%), dizziness (3% vs 2%), headache (3% vs 2%), pruritus (2% vs 1%) and vomiting (1% vs 3%).

**Use in Specific Populations**

**Pregnancy**

There are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Bamlanivimab should only be used during pregnancy if the potential benefit outweighs the potential risk for the mother and the fetus.

**Breastfeeding**

There are no available data on the presence of bamlanivimab in human or animal milk, the effects on the breastfed infant, or the effects on milk production. Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.

Healthcare providers should review the [Fact Sheet for Healthcare Providers](#) for information on the authorized use of bamlanivimab and mandatory requirements of the EUA. Please also see the [FDA Letter of Authorization](#) and the [Fact Sheet for Patients, Parents and Caregivers](#).
SCALING OPERATIONS

The time duration to administer a 700 mg / 20 mL dose of bamlanivimab is 16–60 minutes at the appropriate infusion rate for both infusion pumps and gravity infusion. Treatment also requires a post-infusion observation period. It is clinically recommended to monitor patients during administration and observe patients for at least 1 hour after infusion is complete. Sites of care should follow local recommendations when determining appropriate observation periods. If patients will occupy chairs for infusion during this period, rather than a post-treatment monitoring area, planning must account for this time as well.

The number of chairs for infusion can be scaled along with the hours of operation to determine the size of the infusion site of care. Infusion sites of care should take into account time for patient intake, IV preparation, infusion and post-infusion observation when determining potential capacity. For example, in Lilly’s monoclonal antibody clinical trial settings, Lilly found a single infusion could take between 121–195 minutes to complete from patient intake to discharge. See Appendix A for more information.

The above values could be used to determine a rough approximation of the number of infusion sites of care that may be needed per region. A region can easily modify the number based on changing the capacity assumptions with the various infusion sites of care. Depending on the dispersion of the population in a region, the region may choose to size some infusion sites of care larger than others.
INFUSION SITE OF CARE RECOMMENDATIONS

Preparation, Storage and Handling

Prepare infusions using aseptic technique, in a manner consistent with local laws, regulations, guidelines and policies for outpatient infusion.

- Use aseptic technique and applicable good clinical practice for intravenous solution preparations of bamlanivimab.
- Only use materials which are listed as compatible with bamlanivimab for preparation and administration of the infusion solutions (see Compatible Materials section below).
- Gather the materials for infusion:
  - Polyvinyl chloride (PVC) or polyethylene (PE)-lined PVC infusion set
  - Use of an in-line or add-on 0.20/0.22 micron polyethersulfone (PES) filter is strongly recommended

Bamlanivimab has no known incompatibilities with traditional medical supplies and equipment. Infusion sites of care may determine based on medical best practices what supplies and equipment to use when administering bamlanivimab, including add-on filter devices.

- Use new, sterile syringes and needles to prepare each dosing solution of bamlanivimab.
- Refrigerate bamlanivimab drug product when not in use at 2° C to 8° C (36° F to 46° F).
- Bamlanivimab should be free of any visible particulate matter. Obtain new vial(s) and/or IV bags if the drug product contains any visible particulate matter.
- All medication must be stored, inventoried and destroyed according to applicable regulations.
- Bamlanivimab is administered by intravenous (IV) infusion either using an infusion pump or gravity infusion. Consider use of a rate control or infusion rate monitoring device if using gravity infusion. Tubing with an integrated rate flow regulator can also be considered if an infusion pump is not available.
- The IV solutions are intended for immediate patient administration. If immediate administration is not possible, store the diluted bamlanivimab infusion solution for up to 24 hours at refrigerated temperature (2° C to 8° C [36° F to 46° F]) and up to 7 hours at room temperature (20° C to 25° C [68° F to 77° F]) including infusion time. If refrigerated, allow the infusion solution to equilibrate to room temperature for approximately 20 minutes prior to administration. The hold time includes preparation, solution hold, infusion and flush.
Compatible Materials

Individual infusion sites of care should follow best medical practices when determining materials to use. Procurement of materials from a specific vendor or vendors is not required. If alternate materials are used, the compatibility of these materials should be confirmed with that vendor. Bamlanivimab has no known incompatibilities with conventional medical supplies and equipment. During clinical trials, Lilly has used the following materials:

- Polypropylene syringes
- Stainless steel needles
- Polyvinyl chloride (PVC) IV bags with or without DEHP
- Polyvinyl chloride (PVC) infusion sets with or without DEHP containing an in-line polyethersulfone (PES)* filter (Please see footnote.)

Storage

Bamlanivimab is preservative-free. Discard unused portion. Refrigerate unopened vials at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze, shake or expose to direct light.

Preparation and Administration

Preparation

Bamlanivimab solution for infusion should be prepared by a qualified healthcare professional using aseptic technique.

- The 700 mg dose MUST BE prepared using 0.9% Sodium Chloride.
  - Preparation of 700 mg dose of bamlanivimab for IV infusion
  - Administration of a dose of 700 mg of bamlanivimab in an IV infusion

Refer to Recommended Administration Instructions for Bamlanivimab for additional dose preparation information.

- Gather the materials for preparation:
  - Polyvinyl chloride (PVC) or polyethylene (PE)-lined PVC, sterile pre-filled infusion bag. Choose one of the following sizes:
    - Prefilled 50, 100, 150 or 250 mL infusion bag containing 0.9% Sodium Chloride Injection (See Table 1).
  - One 20 mL vial of bamlanivimab (700 mg/20 mL).

- Remove one bamlanivimab vial from refrigerated storage and allow to equilibrate to room temperature for approximately 20 minutes before preparation. **Do not expose to direct heat. Do not shake the vial.**

- Inspect bamlanivimab visually for particulate matter and discoloration.
  - Bamlanivimab is a clear to opalescent and colorless to slightly yellow to slightly brown solution.

- Withdraw 20 mL bamlanivimab from one 20 mL vial and inject into prefilled infusion bag containing 0.9% Sodium Chloride Injection (see Table 1).

- Discard any product remaining in the vial.

- Gently invert IV bag by hand approximately 10 times to mix. **Do not shake.**

- This product is preservative-free and therefore, the diluted infusion solution should be administered immediately.
  - If immediate administration is not possible, store the diluted bamlanivimab infusion solution for up to 24 hours at refrigerated temperature (2°C to 8°C [36°F to 46°F]) and up to 7 hours at room temperature (20°C to 25°C [68°F to 77°F]) including infusion time. If refrigerated, allow the infusion solution to equilibrate to room temperature for approximately 20 minutes prior to administration.

*If alternate materials are used, the compatibility of these materials should be confirmed with that vendor. Bamlanivimab has no known incompatibilities with conventional medical supplies and equipment.
Administration
Bamlanivimab infusion solution should be administered by a qualified healthcare professional.

- Gather the materials for infusion:
  - Polyvinyl chloride (PVC) or polyethylene (PE)-lined PVC infusion set
  - Use of an in-line or add-on 0.20/0.22 micron polyethersulfone (PES) filter is strongly recommended
- Attach the infusion set to the IV bag.
- Prime the infusion set.
- Administer the entire infusion solution in the bag via pump or gravity according to the size of infusion bag used (see Table 1). Due to potential overfill of pre-filled saline bags, the entire infusion solution in the bag should be administered to avoid underdosage.
- The prepared infusion solution should not be administered simultaneously with any other medication. The compatibility of bamlanivimab with IV solutions and medications other than 0.9% Sodium Chloride Injection is not known.
- Once infusion is complete, flush the tubing with 0.9% Sodium Chloride to ensure delivery of the required dose.
- Clinically monitor patients during administration and observe patients for at least 1 hour after infusion is complete.
- If the infusion must be discontinued due to an infusion reaction, discard any unused product.
- The use of closed system transfer devices (CSTDs), elastomeric pumps, and pneumatic transport with bamlanivimab has not been studied.
- For additional information, please see Fact Sheet for Healthcare Providers.

Table 1: Recommended Dilution and Administration Instructions for Bamlanivimab

<table>
<thead>
<tr>
<th>Drug: Add 20 mL of bamlanivimab (1 vial) to a prefilled infusion bag and administer as instructed below</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Size of Prefilled 0.9% Sodium Chloride Infusion Bag</strong></td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>50 mL</td>
</tr>
<tr>
<td>100 mL</td>
</tr>
<tr>
<td>150 mL</td>
</tr>
<tr>
<td>250 mL</td>
</tr>
</tbody>
</table>

* 700 mg of bamlanivimab (20 mL) is added to an infusion bag and administered as a single intravenous infusion.
Calculating Drip Rate for Gravity Infusion

*For gravity infusions, please use the following formula to calculate drip rate:*

\[
\text{Drip Rate Formula} \\
\frac{\text{Volume to be infused (in mL) \times Drop factor (see tubing package)}}{\text{Total infusion time (in minutes)}} = \text{Drip rate (in drops/min)}
\]

For additional information, please see [Fact Sheet for Healthcare Providers](#).

---

**Note:** After the appropriate infusion volume has been administered, flush the tubing with 0.9% Sodium Chloride as per infusion site of care recommendations or with sufficient volume to flush residual volume from tubing to ensure the patient receives the entire dose. Discard unused product.
Recommended Infusion Site of Care Resources and Equipment Considerations
**STAFFING RECOMMENDATIONS**

Staffing recommendations may vary by state. Follow your local recommendations when determining the staff needed for your infusion site of care. Based on Lilly’s clinical trial experience, the following roles should be considered to ensure the safest care environment for patients receiving bamlanivimab antibody infusion.

Infusion sites of care should have appropriately trained medical staff to administer infusion treatments and identify and manage potential adverse reactions. It is recommended that participants who experience a systemic hypersensitivity reaction be treated per the local standard of care.

IV admixture should be prepared in a dedicated area with a working sink available. Depending on their role in the infusion unit, all individuals may be trained to wear PPE.

<table>
<thead>
<tr>
<th>Role</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patient intake</strong></td>
<td>Person with basic administrative skills</td>
</tr>
<tr>
<td><strong>Drug infusion preparation</strong></td>
<td>Healthcare professional trained in IV admixture preparation (such as a nurse, pharmacist, pharmacy tech)</td>
</tr>
<tr>
<td><strong>Infusion: start IV</strong></td>
<td>Healthcare professional trained to start an IV</td>
</tr>
<tr>
<td><strong>Infusion: administer infusion</strong></td>
<td>Healthcare professional trained in IV infusion administration (such as a nurse, pharmacist, pharmacy tech)</td>
</tr>
<tr>
<td><strong>Infusion monitoring</strong></td>
<td>Healthcare professional trained in:</td>
</tr>
<tr>
<td></td>
<td>• assessing infusion-related reactions</td>
</tr>
<tr>
<td></td>
<td>• treating infusion-related reactions</td>
</tr>
<tr>
<td></td>
<td>• vital sign monitoring</td>
</tr>
<tr>
<td><strong>Post-infusion observation</strong></td>
<td>Healthcare professional trained in:</td>
</tr>
<tr>
<td></td>
<td>• assessing infusion-related reactions</td>
</tr>
<tr>
<td></td>
<td>• treating infusion-related reactions</td>
</tr>
<tr>
<td></td>
<td>• vital sign monitoring</td>
</tr>
<tr>
<td></td>
<td>• providing post-infusion education for the patient</td>
</tr>
<tr>
<td><strong>Patient release</strong></td>
<td>Person with basic administrative skills</td>
</tr>
<tr>
<td><strong>Waste removal and cleaning</strong></td>
<td>Person trained in COVID-19 cleaning and disinfection</td>
</tr>
</tbody>
</table>

**Notes:**

- At least one healthcare professional should have Advanced Cardiovascular Life Support (ACLS) or Basic Life Support (BLS) certification or equivalent.
- At least one healthcare professional should be able to respond to medical emergency (e.g., severe infusion reaction); any specific certifications based on state and healthcare facility regulations and policies.
- The same healthcare professional may perform more than one role.
- State or country recommendations may dictate specific qualifications for some roles.
INFUSION SITE OF CARE MATERIALS

Equipment recommendations may vary by state. Follow your local recommendations when determining the equipment needed for your infusion site of care. Based on Lilly’s clinical trial experience, the following equipment should be considered to ensure the safest infusion site of care environment for patients receiving bamlanivimab antibody infusion. Additional recommended equipment and emergency medical supplies can be found in Appendix B.

Below are recommended non-consumable materials which are needed in an infusion site of care:

- Infusion pumps (if available)
- Infusion pump bracket for IV pole (if available)
- Chairs for infusion
- Mobile IV poles
- Emergency medical management equipment and backboard, including a reaction management kit (see Appendix B)
- Chairside table
- Locking refrigerator with temperature monitoring capability
- Transilluminator (vein finder)
- Vital sign monitoring equipment (see Appendix B)

Below are recommended consumable items which are needed in an infusion site of care:

<table>
<thead>
<tr>
<th>Consumable Items</th>
<th>Recommended supplies are based on Lilly’s clinical trial experience.</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPE</td>
<td>IV and catheters* 0.20/0.22 µm filter 50, 100, 150 or 250 mL 0.9% Sodium Chloride PVC or PE-lined PVC IV bags Prefilled 0.9% Sodium Chloride syringes Appropriately sized syringes Alcohol wipes 2x2 gauze pads Adhesive bandages Tegaderm™ bio-occlusive dressing Absorbent underpads (blue pads) Extension set tubing Sterile needles - stainless steel 18ga IV administration sets (tubing) Sharps containers Transpore™ tape</td>
</tr>
<tr>
<td></td>
<td>Biohazard disposal bag Disposable disinfecting wipes Thermometer probe covers (if required) 70% alcohol wipes Paper towels Trash bins and liners Infusion Reaction Kit (see Appendix B)</td>
</tr>
</tbody>
</table>

Listed supplies are reflective of quantities/volumes used in Lilly clinical trials. Infusion sites of care may substitute alternate quantities and volumes as needed based on best medical practices and local recommendations.

*24 g catheter is sufficient.
CONSIDERATIONS FOR RESIDENTS OF LONG TERM CARE FACILITIES

The COVID-19 pandemic presents unique challenges to long-term care facilities. Residents of long term care facilities account for only 5% of U.S. cases but 34% of U.S. deaths from COVID-19†. It is critical that available treatments, such as bamlanivimab, are accessible to these facilities and the residents they care for. Below, find information about receiving infusion treatments, reimbursement and unique considerations for long term care facilities administering bamlanivimab.

†Numbers accurate as of March 2021. Source: Kaiser Family Foundation

Receiving Infusion Treatments

Long term care pharmacy providers will typically receive infusion treatments from a long term care pharmacy, hospital pharmacy network or contract pharmacy network.

Long Term Care Recommended Resources and Equipment Considerations

Long term care facilities may need to take unique equipment considerations into account. In addition to resources and equipment recommendations outlined in other parts of this Playbook (See Section 5 and Appendix B), long term care facilities should consider the following:

- Needles (18 gauge may be incompatible with this population)
- Pharmacy/transportation considerations
COMBATING COVID-19

Attacking the coronavirus will require a diverse set of approaches, including both vaccines and treatments, such as antibodies.

Q. What’s the difference between vaccines and monoclonal antibody drugs?

A. While there are some similarities, here’s how they are different:

- Monoclonal antibody drugs, like bamlanivimab, provide passive immunity by giving the body antibodies to protect itself. Vaccines provide active immunity by helping the body make its own antibodies to protect itself.
- Monoclonal antibody drugs are designed to start working faster than vaccines, while protection provided by vaccines will generally last longer.
- Generally, scientists are able to develop antibody treatments faster than they are able to develop vaccines.

Developing any approach against COVID-19 involves assessing key factors:

Viral exposure
A vaccine will not help an already-infected patient

Stage of disease
When to apply the medicine to prevent the infection or treat the disease

At-risk populations
Factors linked to worse outcomes (e.g., age, concurrent diseases)
NEUTRALIZING ANTIBODIES AS POTENTIAL TREATMENTS

Identified and characterized using various methods, including from the blood of COVID-19 survivors, neutralizing antibodies target the viral spike protein that SARS-CoV-2 uses to gain entry into host cells. Neutralizing antibodies, therefore, are specifically designed to treat COVID-19.

Q. What are antibodies?

A. Antibodies are naturally made in our bodies to fight infection.

- Whenever the immune system meets a new foreign substance in the body, it makes new antibodies that attack the foreign substance. The next time that substance shows up, the immune system can produce the same antibodies to help the body fight it off before it can make a person sick. These types of naturally occurring antibodies provide active immunity.
- Vaccines work in a similar way, helping the body make antibodies to attack specific foreign substances and providing active immunity in the body.
- Antibody drugs are different. They are man-made antibodies that are given directly through an infusion or injection rather than prompting the body to make the antibodies for itself. This type of immunity is called passive immunity.

Find more information about monoclonal antibody drugs and vaccines from the CDC, State Health Departments, and the following resources:

- [CombatCOVID.HHS.gov](https://CombatCOVID.HHS.gov)
- [www.coronaviruspreventionnetwork.org](https://www.coronaviruspreventionnetwork.org)
- [www.infusioncenter.org](https://www.infusioncenter.org) (National Infusion Center Association)
- [Fact Sheet for Healthcare Providers](https://www.infusioncenter.org)
- [Fact Sheet for Patients, Parents and Caregivers (English)](https://www.infusioncenter.org)
- [Fact Sheet for Patients, Parents and Caregivers (Spanish)](https://www.infusioncenter.org)
- [FDA Letter of Authorization](https://www.infusioncenter.org)
Monoclonal Antibodies

What are antibodies?
Antibodies are naturally made in our bodies to fight infection.

Without Antibodies
A virus enters a cell
Cell lining

With Antibodies
Antibodies block the virus from entering the cell

What are MONOCLONAL ANTIBODIES?
Monoclonal antibodies (mAbs) are antibodies developed in a laboratory to help our bodies fight infection.

Nearly 100
mAbs are FDA approved to treat health conditions including cancers and autoimmune diseases.
mAbs are also being studied for the treatment and prevention of COVID-19.

How are mAbs administered?
mAbs are given through intravenous infusion (i.e., through a vein) or injection.

OR

What are common side effects of mAbs?
Allergic reactions  Flu-like symptoms  Nausea & vomiting  Diarrhea  Low blood pressure

COVID-19 Prevention Network
PreventCOVID.org
APPENDIX A

Lilly Monoclonal Antibody Clinical Trial Modeling Information
LILLY MONOCLONAL ANTIBODY
CLINICAL TRIAL MODELING INFORMATION

Assuming the infusion site of care setup details provided below, this information can be used to model the estimated number of infusions (patients) an infusion site of care can serve, depending on its capacity.

Each infusion site of care will vary in terms of the amount of chairs for infusion, staffing considerations, work day length and more. The information provided here is meant as a general guide based upon Lilly’s clinical trial experience. In some cases, ideal criteria are included, such as for observation time. In other instances, such as the patient education and intake time, there are estimated ranges shown, with “+” or “-” conditions in parentheses.

### Infusion Timing

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Details</th>
<th>Additional Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient education and intake</td>
<td>30 min (+/- 15 min)</td>
<td>Patient education and intake may occur outside of the infusion chair, such as at the prescriber's location, and patient education and intake time may vary per patient.</td>
</tr>
<tr>
<td>IV prep time</td>
<td>30 min</td>
<td>This step usually does not take place until the patient is in the chair for infusion and vascular access has been obtained.</td>
</tr>
<tr>
<td>Infusion time</td>
<td>16 – 60 min</td>
<td>Infusion time should be a minimum of 16-60 minutes, although more time may be necessary.</td>
</tr>
<tr>
<td>Observation time*</td>
<td>60 min</td>
<td>It is clinically recommended to monitor patients during infusion and observe patients for at least 1 hour after infusion is complete, although more time may be necessary. Sites of care should follow local recommendations when determining appropriate observation periods.</td>
</tr>
<tr>
<td><strong>TOTAL TIME</strong></td>
<td><strong>121 – 195 min</strong></td>
<td>This represents the estimated total time from patient education through observation of the patient.</td>
</tr>
</tbody>
</table>

*It is recommended that infusion sites of care have a protocol in place for patients who refuse to stay for post-infusion observation. For example, this may include an AMA form, release of responsibility waiver, etc.*
APPENDIX B

Basic Equipment Recommendations
# Basic Equipment Recommendations

Equipment recommendations may vary by state. Follow your local recommendations when determining the equipment needed for your infusion center. Based on Lilly’s clinical trial experience, the following equipment should be considered to ensure the safest care environment for patients receiving bamlanivimab antibody infusion.

## Basic Equipment Recommendations

<table>
<thead>
<tr>
<th>Drug preparation</th>
<th>Patient intake and release</th>
</tr>
</thead>
<tbody>
<tr>
<td>Locked refrigerator with min/max temp monitoring</td>
<td>Signage with patient instructions</td>
</tr>
<tr>
<td>Prep table or area</td>
<td>Phone for intake worker</td>
</tr>
<tr>
<td>18 ga needles</td>
<td>Schedule or list of appointments</td>
</tr>
<tr>
<td>Appropriate sized syringes</td>
<td>Office supplies (e.g. pens, stapler, scissors, paper clips, etc.)</td>
</tr>
<tr>
<td>50, 100, 150 or 250 mL 0.9% Sodium Chloride PVC or PE-lined PVC IV bags</td>
<td>Clipboard with patient intake and monitoring sheet</td>
</tr>
<tr>
<td>Sterile alcohol prep pads</td>
<td>Patient intake and monitoring form</td>
</tr>
<tr>
<td>PPE gloves all sizes</td>
<td>Check-in table</td>
</tr>
<tr>
<td>PPE face shields or goggles (only if prepared in the COVID-19 unit)</td>
<td>Chair(s) for check-in staff</td>
</tr>
<tr>
<td>PPE N95 masks (only if prepared in the COVID-19 unit)</td>
<td>Bleach sanitizing wipes</td>
</tr>
<tr>
<td>Sharps containers</td>
<td>Hand sanitizer</td>
</tr>
<tr>
<td>Drug transport bags (if using mobile pharmacy)</td>
<td>PPE gloves all sizes</td>
</tr>
<tr>
<td>Alcohol sanitizing wipes</td>
<td>PPE face shields or goggles</td>
</tr>
<tr>
<td>Step-by-step instruction sheet (with images)</td>
<td>PPE N95 masks</td>
</tr>
<tr>
<td></td>
<td>PPE gowns</td>
</tr>
</tbody>
</table>
## Basic Equipment Recommendations

### Infusion area supplies
- Chairs for infusion
- Chairside table
- IV poles
- IV pump (or gravity feed)
- Vital signs monitoring equipment (BP, HR, resp rate, temp, O₂ sat)
- Supply cart or other storage cabinet
- Hand sanitizer
- Hand soap
- Biohazard trash can
- Bleach wipes (cleaning non-electronic equipment)
- Alcohol wipes (cleaning electronic equipment)
- Medical emergency supplies
- Sterile alcohol prep pads
- IV catheters
- IV extension tubing
- Tourniquet
- PVC infusion sets
- 0.20/0.22 µm filter
- Gauze pads
- Adhesive bandages
- 0.9% Sodium Chloride flush syringes
- Bio-occlusive dressing
- Tape
- 50 mL 0.9% Sodium Chloride IV bag or 20 mL 0.9% Sodium Chloride syringe to flush the tubing following infusion
- PPE gloves all sizes
- PPE face shields or goggles
- PPE N95 masks
- PPE gowns

### Observation area
- Vital signs monitoring equipment (BP, HR, resp rate, temp, O₂ sat)
- Table for staff
- Chairs for patients and staff
- Bleach sanitizing wipes
- Hand sanitizer
- PPE gloves all sizes
- PPE face shields or goggles
- PPE N95 masks
- PPE gowns
# MEDICAL EMERGENCY SUPPLIES AND MEDICATIONS

Emergency medical management equipment should contain the following items:

*Some medications listed below should only be administered by a healthcare provider with ACLS training*

<table>
<thead>
<tr>
<th></th>
<th>Essential</th>
<th>Recommended</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medications</strong></td>
<td>Albuterol inhaler&lt;br&gt;Diphenhydramine injection&lt;br&gt;Epinephrine 0.1 mg/mL  (1 mg / 10 mL) OR epinephrine auto-injector 0.3 mg&lt;br&gt;Solu-Medrol injection</td>
<td>Adenosine injection&lt;br&gt;Atropine sulfate&lt;br&gt;Chewable ASA&lt;br&gt;Dextrose 50% injection&lt;br&gt;Insta glucose&lt;br&gt;Nitroglycerine&lt;br&gt;Ondansetron injection&lt;br&gt;Sodium bicarbonate injection</td>
</tr>
<tr>
<td><strong>IV supplies</strong></td>
<td>0.9% Sodium Chloride flush (10 mL)&lt;br&gt;0.9% Sodium Chloride bag (500 mL)</td>
<td>IV admin set&lt;br&gt;IV start kit&lt;br&gt;IV catheter&lt;br&gt;Non-DEHP cath/extension set&lt;br&gt;5% dextrose bag</td>
</tr>
<tr>
<td><strong>Airway</strong></td>
<td></td>
<td>Nasopharyngeal/oral airway suction&lt;br&gt;Barrier mask for CPR&lt;br&gt;Ambu Bag&lt;br&gt;Oxygen and airway equipment</td>
</tr>
<tr>
<td><strong>Emergency medical management</strong></td>
<td>Infusion sites of care should have a standard operating procedure in place instructing infusion site of care staff how emergency events should be managed, including appropriate contacts (911, physician, etc.), ACLS protocol and any follow-up activities.</td>
<td></td>
</tr>
</tbody>
</table>